Murai K, Hirano H, Utsugisawa T, Takeda R, Narigasawa Y, Kanazawa T, Miyairi Y, Kuriya S
Department of Medicine III, School of Medicine, Iwate Medical University.
Rinsho Ketsueki. 1993 Feb;34(2):207-11.
A 63-year-old female with chronic idiopathic thrombocytopenic purpura refractory to prednisolone therapy was treated with interferon alpha-2b (IFN alpha-2b). Initially, the patient received 2 courses of short-course therapy in which 1.5 million IU and IFN alpha-2b was subcutaneously injected 3 times a week every other day for 4 weeks. During the first course, the platelet count rose from 1.0 x 10(4)/microliters to 12.4 x 10(4)/microliters 3 weeks after the beginning of the therapy, but the effect was transient. In the second course the platelet-increasing effect was lower than that in the first course. Then, intermittent injections of 3 million IU of IFN alpha-2b once a week were subsequently begun. Consequently, the patient's platelet count has been maintained at 5 to 9 x 10(4)/microliters for more than 19 months since the beginning of intermittent IFN alpha-2b therapy.
一名63岁女性,患有慢性特发性血小板减少性紫癜,对泼尼松龙治疗无效,接受了α-2b干扰素(IFNα-2b)治疗。最初,患者接受了2个疗程的短程治疗,每次皮下注射150万国际单位IFNα-2b,每周3次,隔日注射,共4周。在第一个疗程中,治疗开始3周后血小板计数从1.0×10⁴/微升升至12.4×10⁴/微升,但效果是短暂的。在第二个疗程中,血小板增加效果低于第一个疗程。随后开始每周一次间歇性注射300万国际单位的IFNα-2b。因此,自开始间歇性IFNα-2b治疗以来,患者的血小板计数在5至9×10⁴/微升维持了超过19个月。